| ￥1200 | |
| A05300-50 | |
|
|
|
|
|
|
|
|
|
| Specificity | This product is specific to Caveolin 3 |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human Caveolin 3 |
| Species Reactivity | Human |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||||||
|
|||||||||
| Form | Liquid |
| Storage Buffer | Supplied in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol. |
| Storage Instructions | Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. |
| Purification | Affinity-chromatography |
| Isotype | Rabbit IgG |
| Clonality | Monoclonal |
Western blot analysis of Caveolin-3 expression in human skeletal muscle cell lysate. »
| Target Background | May act as a scaffolding protein within caveolar membranes. Interacts directly with G-protein alpha subunits and can functionally regulate their activity. May also regulate voltage-gated potassium channels. Plays a role in the sarcolemma repair mechanism of both skeletal muscle and cardiomyocytes that permits rapid resealing of membranes disrupted by mechanical stress. |
| Synonyms | CAV3; Caveolin 3; LGMD1C; LQT9; M-caveolin; VIP21; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
